bosentan anhydrous has been researched along with Disease Exacerbation in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 16 (50.00) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Sakao, S; Tanabe, N; Tatsumi, K | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Al-Hiti, H; Galiè, N; Hoeper, MM; Jansa, P; Kusic-Pajic, A; Lemarié, JC; Meyer, GM; Rubin, LJ; Simonneau, G | 1 |
| Morrell, NW; Pepke-Zaba, J; Sheares, K; Soon, E; Southwood, M | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Glukhova, SI; Iudkina, NN; Kurmukov, IA; Nasonov, EL; Nikolaeva, EV; Volkov, AV | 1 |
| Amoroso, D; Barbano, B; Di Paolo, M; Gigante, A; Palange, P; Romaniello, A; Rosato, E; Tallerini, G | 1 |
| Ballas, K; Emoniotou, E; Kalodimos, G; Koukoulis, G; Marakis, G; Papamichali, R; Pavlidis, T; Psarras, K; Rafailidis, S; Sakadamis, A | 1 |
| D'Armini, AM; Delcroix, M; Ghofrani, HA; Hoeper, MM; Jaïs, X; Jansa, P; Lang, IM; Mayer, E; Morganti, A; Pepke-Zaba, J; Perchenet, L; Rubin, LJ; Simonneau, G; Torbicki, A | 1 |
| Cella, G; Cozzi, F; Fareed, J; Iqbal, O; Marotta, H; Saggiorato, G; Tona, F; Vianello, F | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Barst, RJ; Brand, M; Ivy, DD; Lemarié, JC; Rosenberg, D; Rosenzweig, EB | 1 |
| Dwyer, N; Kilpatrick, D | 1 |
| Foster, H; Haworth, SG; Hislop, AA; Moledina, S; Schulze-Neick, I | 1 |
| Behr, J; Brown, KK; du Bois, RM; King, TE; Leconte, I; Lynch, DA; Martinez, F; Morganti, A; Raghu, G; Roux, S; Valeyre, D | 1 |
| Lau, EM; McCaughan, GW; Torzillo, PJ | 1 |
| Fedele, F; Pezzuto, B; Rubin, LJ; Vizza, CD | 1 |
| Daniels, CJ | 1 |
| Boutou, A; Kontou, P; Paspala, A; Pitsiou, G; Sourla, E; Stanopoulos, I | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Adatia, I | 1 |
| Cochrane, AD; Davis, AM; Penny, DJ; Rose, ML; Simpson, CM; Weintraub, RG; Wilson, SE | 1 |
| Bonderman, D; Hughes, RJ; Humbert, M; Jais, X; Lang, I; Pepke-Zaba, J; Simonneau, G; Suntharalingam, J | 1 |
| Badesch, D; Barst, RJ; Frost, A; Galie, N; Langleben, D; Lawrence, EC; Naeije, R; Shapiro, S | 1 |
| Sastry, BK | 1 |
| Gabbay, E; Reed, A; Williams, TJ | 1 |
| Jiao, WJ; Pan, H; Shen, Y; Wang, TY; Xu, J | 1 |
| Behr, J; Brown, KK; de Andrade, JA; du Bois, RM; King, TE; Lancaster, L; Leconte, I; Raghu, G; Roux, S; Stähler, G | 1 |
| Park, MH | 1 |
| Benati, L; Benigni, A; Corna, D; Facchinetti, D; Orisio, S; Remuzzi, G; Zola, C | 1 |
| Goldstein, S; Mishima, T; Sabbah, HN; Sharov, VG; Suzuki, G; Tanimura, M; Todor, A | 1 |
| Inagaki, K; Iwanaga, Y; Kataoka, K; Kihara, Y; Onozawa, Y; Sasayama, S; Yoneda, T | 1 |
7 review(s) available for bosentan anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Topics: Bosentan; Disease Progression; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Circulation; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Pyrazoles; Pyrimidines; Sildenafil Citrate; Treatment Failure; Vascular Remodeling; Vasoconstriction | 2019 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
Bosentan for the treatment of adult pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Comorbidity; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Prognosis; Quality of Life; Receptors, Endothelin; Sulfonamides | 2011 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
Pharmacologic treatment for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Progression; Drug Therapy, Combination; Endothelin-1; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Prognosis; Prostaglandins; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Topics: Adolescent; Adult; Aged; Arterioles; Australia; Bosentan; Cardiac Catheterization; Diagnostic Imaging; Disease Progression; Dyspnea; Endothelin A Receptor Antagonists; Epoprostenol; Exercise Test; Female; Forecasting; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Nitric Oxide; Piperazines; Prognosis; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
6 trial(s) available for bosentan anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Topics: Antihypertensive Agents; Bosentan; Disease Progression; Double-Blind Method; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Risk Factors; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
[Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
Topics: Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Lupus Erythematosus, Systemic; Male; Middle Aged; Scleroderma, Systemic; Sulfonamides; Survival Rate; Treatment Outcome | 2014 |
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Disease Progression; Double-Blind Method; Endarterectomy; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Severity of Illness Index; Sulfonamides; Thromboembolism | 2008 |
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pulmonary Diffusing Capacity; Quality of Life; Sulfonamides; Survival Rate; Vital Capacity | 2011 |
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Risk Assessment; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise Test; Female; Forced Expiratory Volume; Humans; Long-Term Care; Male; Middle Aged; Prospective Studies; Pulmonary Fibrosis; Quality of Life; Sulfonamides; Survival Rate; Tomography, Spiral Computed; Treatment Outcome; Vital Capacity | 2008 |
19 other study(ies) available for bosentan anhydrous and Disease Exacerbation
| Article | Year |
|---|---|
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arteriovenous Malformations; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Mutation; Pedigree; Piperazines; Pulmonary Artery; Pulmonary Veins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Bosentan for digital ulcers prevention does not worsen cardiopulmonary exercise test parameters in SSc patients with interstitial lung disease.
Topics: Adult; Bosentan; Disease Progression; Endothelin Receptor Antagonists; Exercise Test; Female; Fingers; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Receptor, Endothelin A; Respiratory Function Tests; Scleroderma, Systemic; Skin Ulcer; Statistics as Topic; Sulfonamides; Treatment Outcome | 2016 |
Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal and Gastric Varices; Follow-Up Studies; Liver; Liver Cirrhosis, Experimental; Male; Portal Pressure; Rats; Rats, Wistar; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Connective Tissue Diseases; Disease Progression; Endothelial Cells; Endothelium, Vascular; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2009 |
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
Topics: Antihypertensive Agents; Bosentan; Child; Connective Tissue Diseases; Disease Progression; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Treatment Outcome | 2010 |
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
Topics: Adolescent; Algorithms; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pulmonary Medicine; Retrospective Studies; Sulfonamides; Treatment Outcome | 2011 |
A case of portopulmonary hypertension spanning 18 years: successful use of bosentan for progressive disease after two liver transplantations.
Topics: Bosentan; Disease Progression; Female; Humans; Hypertension, Pulmonary; Hypertension, Renal; Liver Transplantation; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Drug Interactions; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Receptor, Endothelin B; Sulfonamides | 2012 |
Adult congenital heart disease and pulmonary hypertension: management of a complex case.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Dyspnea; Eisenmenger Complex; Exercise Test; Follow-Up Studies; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Oxygen; Pulmonary Valve Stenosis; Sulfonamides | 2012 |
A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges.
Topics: Adult; Bosentan; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Iloprost; Lung; Lung Transplantation; Male; Piperazines; Pulmonary Artery; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tomography, X-Ray Computed; Vasodilator Agents; Waiting Lists | 2013 |
Improving the outcome of childhood pulmonary arterial hypertension: the effect of bosentan in the setting of a dedicated pulmonary hypertension clinic.
Topics: Antihypertensive Agents; Bosentan; Child; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2005 |
Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension.
Topics: Age Factors; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Female; Humans; Hypertension, Pulmonary; Male; Sulfonamides; Survival Analysis | 2006 |
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Bosentan; Disease Progression; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Sulfonamides; Thromboembolism; Time Factors; Treatment Outcome | 2006 |
Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B.
Topics: Antihypertensive Agents; Bosentan; Carcinoma, Squamous Cell; Cathepsin B; Cell Line, Tumor; Collagen; Disease Progression; Drug Combinations; Endothelin-1; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Laminin; Neoplasm Invasiveness; Neovascularization, Pathologic; Proteoglycans; Sulfonamides | 2007 |
Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.
Topics: Analysis of Variance; Animals; Blotting, Northern; Bosentan; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Gene Expression Regulation; Humans; Kidney; Kidney Diseases; Male; Nephrectomy; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Sulfonamides | 1996 |
Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dogs; Heart Failure; Infusions, Intravenous; Myocardium; Stroke Volume; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2000 |
Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Progression; Endothelin-1; Endothelins; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Male; Organ Size; Peptidyl-Dipeptidase A; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Survival Analysis; Thiazepines; Time Factors | 2001 |